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Abstract 
Background: Randomised controlled trials have demonstrated significant reductions in 
colorectal cancer (CRC) incidence and mortality associated with polypectomy.  However, little 
is known about whether polypectomy is effective at reducing CRC risk in routine clinical 
practice.  The aim of this investigation was to quantify CRC risk following polypectomy in a 
large prospective population-based cohort study. 
Methods: Patients with incident colorectal polyps between 2000 and 2005 in Northern Ireland 
(NI) were identified via electronic pathology reports received to the NI Cancer Registry 
(NICR).  Patients were matched to the NICR to detect CRC and deaths up to 31st December 
2010.  CRC standardised incidence ratios (SIRs) were calculated and Cox proportional hazards 
modelling applied to determine CRC risk.   
Results: During 44,724 person-years of follow-up, 193 CRC cases were diagnosed amongst 
6,972 adenoma patients, representing an annual progression rate of 0.43%.  CRC risk was 
significantly elevated in patients who had an adenoma removed (SIR 2.85; 95% CI: 2.61 to 
3.25) compared with the general population.  Male sex, older age, rectal site and villous 
architecture were associated with an increased CRC risk in adenoma patients.  Further analysis 
suggested that not having a full colonoscopy performed at, or following, incident polypectomy 
contributed to the excess CRC risk. 
Conclusions: CRC risk was elevated in individuals following polypectomy for adenoma, 
outside of screening programmes.   
Impact: This finding emphasises the need for full colonoscopy and adenoma clearance, and 
appropriate surveillance, after endoscopic diagnosis of adenoma.  
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Introduction  
In the UK, colorectal cancer (CRC) is the fourth most common incident cancer and second 
most common cause of cancer-related death.(1)  The UK has inferior CRC survival rates to 
comparable countries, commonly attributed to later clinical presentation.(2, 3)  CRC typically 
originates from precancerous colorectal polyps, providing an opportunity for prevention if 
detected early and successfully excised.   
 
The vast majority of colorectal polyps are either adenomas or hyperplastic polyps.(4)  
Adenomas are dysplastic polyps which can progress via the adenoma-carcinoma sequence to 
invasive cancer.  Hyperplastic polyps are classified within the serrated group of colorectal 
polyps, and are traditionally considered benign.  A related subtype of serrated polyps, namely 
sessile serrated polyps (also known as sessile serrated adenomas), may progress to carcinoma 
via the serrated carcinogenesis pathway,(5, 6) but these are relatively rare.(7)  Individuals who 
have only hyperplastic polyps removed at endoscopy are not typically entered into 
surveillance.(8)  Individuals with adenomas detected will usually be entered into a surveillance 
regime at an interval of 1, 3 or 5  years  primarily depending on the number and size of 
adenomas detected or genetic predisposition to CRC.(8, 9)  
 
The ultimate aim of clearing the bowel of adenomas, and entering patients into surveillance, is 
to reduce CRC risk.  Building upon the historic findings of Winawer and colleagues,(10) 
several recent randomised controlled trials(11-14)  and population-based case-control 
studies(15, 16) have demonstrated the success of polypectomy in reducing CRC risk.  The US 
Prostate, Lung, Colorectal and Ovarian cancer screening trial has reported a significant 21% 
reduced risk of CRC amongst the intervention arm who underwent flexible sigmoidoscopy at 
baseline plus 3 or 5 years later, compared with usual care.(11)  A ‘one-off’ flexible 
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sigmoidoscopy was also effective at reducing CRC risk by 23% in a UK trial,(12) while similar 
reductions were observed in Italian, but not Norwegian, trials.(13, 14)    
 
However, little is known about whether polypectomy is effective at reducing CRC risk in 
routine clinical practice.  The aforementioned trials(11-14) and case-control studies(15, 16) 
may incur selection bias due to modest response rates limiting the likelihood of participants 
being representative of the general population.  Few studies have investigated CRC risk 
following polypectomy in the general population.  A French study observed a 2.2-fold greater 
incidence of CRC amongst advanced adenoma patients compared with the general 
population,(17) whilst a large Dutch study concluded that excess CRC risk in adenoma patients 
was limited to the first few years of follow-up.(18) In addition, given the enhanced opportunity 
for polyp detection within bowel cancer screening programmes,(19, 20) the appropriate clinical 
management of patients following polypectomy is even more pertinent. 
 
The aim of this investigation was to quantify CRC risk following polypectomy of adenomas in 
a large population-based study.   
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Materials and Methods 
Subject classification 
The Northern Ireland colorectal polyp register (NICPR) was derived from electronic pathology 
reports relating to all colorectal biopsies within Northern Ireland between 2000 and 2005.  The 
NICPR has ethical approval from ORECNI: 10/NIR02/53.  This timeframe precedes bowel 
cancer screening in this region, and therefore reflects clinical investigation of a symptomatic 
population.  As outlined in Figure 1, relevant SNOMED morphology codes for adenomas and 
hyperplastic polyps were extracted.  Few polyps were diagnosed or coded as sessile serrated 
polyps during this time period, and therefore these were excluded from analysis.  Individuals 
aged <16 years were also removed.  We applied two strategies for identifying and excluding 
patients who may be genetically predisposed to CRC due to polyposis syndromes.  Firstly, 
patients were removed from the NICPR if they attended a genetic follow-up service at the 
Belfast Health and Social Care Trust (the sole referral centre in Northern Ireland). Secondly, 
we conducted a medical note review as part of a nested case-control study (described in detail 
below) to identify participants with a personal or family history of colorectal polyps or 
polyposis syndromes.  
 
Patients were categorised into an ‘adenoma register’ if their incident polyp was recorded as an 
adenomatous polyp(s) with or without a concurrent hyperplastic polyp(s) diagnosis.  Patients 
who only received a hyperplastic polyp diagnosis were grouped into a ‘hyperplastic polyp 
register’.  SNOMED coding was used to identify tubular, tubulovillous or villous adenoma 
subtypes.  Information on polyp size was not readily available, and so patients with ‘advanced 
risk’ adenomas were considered to be those with multiple adenomas of any histological type 
or at least one adenoma including a villous component i.e. villous or tubulovillous.  In order to 
minimise misclassification of polyps detected but not removed at first investigation, all polyps 
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detected within six months of the baseline polyp were reclassified as ‘incident’ polyps.  
Subsequent polyps were those diagnosed at least six months after incident polyps, and up to 
31st December 2005. 
 
Outcome classification 
The Northern Ireland Cancer Registry collects information on all cancer diagnoses since 1993. 
All individuals diagnosed with CRC (ICD-10 codes C18-C20) up to 31st December 2010 were 
matched on the basis of name, date of birth and/or address to the NICPR.  Individuals with a 
previous or concurrent CRC diagnosis were excluded from the NICPR.  CRC cases diagnosed 
at least six months after their incident polyp were considered to be incident CRC, and were 
considered for further case note review as part of a nested case-control study, as detailed below.  
The NICPR was also matched to death records supplied by the Northern Ireland Registrar 
General’s Office to the Northern Ireland Cancer Registry to detect patients who died by 31st 
December 2010. 
 
Nested case control study 
Patients who developed CRC at least six months post-incident polyp diagnosis were included 
in a nested case-control study.  Controls were matched 1:1 to CRC cases by age (±1 year), sex, 
year of incident polyp diagnosis and were alive at the time of their matched cases’ CRC 
diagnosis.  Tumour verification officers reviewed hospital case notes for information on all 
CRC and polyp diagnoses, polyp characteristics (including size, number and dysplasia grade), 
personal and family history of chronic bowel diseases and all lower gastrointestinal 
investigations conducted (including endoscopies) from one year prior to incident polyp 
diagnosis up to end of follow-up.  A small number of individuals who were found to have a 
personal history of polyposis syndromes (or a family history of colorectal polyps as a proxy 
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for an undiagnosed polyposis syndrome) were excluded from further nested case-control study 
analysis due to the likelihood that they are genetically predisposed to CRC.  We did not exclude 
individuals reporting a family history of CRC, since only a small proportion (5-10%)(21) of 
these cases are likely to be due to genetic conditions and a known family history may simply 
reflect shared lifestyle or other non-hereditary CRC risk factors between family members.  
Cases for whom we were able to retrieve notes to enable inclusion within the case-control study 
did not differ from those not included with respect to age, sex, polyp location, morphology or 
advanced status, and are therefore representative of the entire CRC case set. 
   
Statistical analysis  
Patients were followed up from the date of their incident polyp diagnosis (excluding the first 
six months of follow-up) until their date of CRC diagnosis, date of death or 31st December 
2010.  Descriptive characteristics were compared using independent t-tests and chi-squared 
tests for continuous and categorical variables, respectively.  Individuals with less than six 
months follow-up were excluded from analysis.  CRC incidence was calculated per 100-person 
years of follow-up, comparing observed incidence with that of expected incidence in the 
Northern Ireland population between 2000 and 2010.  Cox proportional hazards models were 
applied to investigate the association between CRC risk and demographics or incident polyp 
characteristics.  Stratified analysis was conducted by these variables to explore effect 
modification.  Assumptions for Cox proportional hazards models were checked by visual 
inspection of Kaplan-Meier plots.  Standardised CRC incidence ratios (SIRs) and 
corresponding 95% confidence intervals (CI) were analysed per 100,000 population, and 
separately for males and females.  Sensitivity analysis was performed after excluding those 
with less than one year of follow-up.  For the nested case-control study, CRC risk was assessed 
between comparative groups by applying conditional logistic regression analysis to generate 
9 
 
odds ratios (OR) and 95% CI.  Statistical analysis was conducted using Intercooled Stata 
version 11.0 (StataCorp, College Station, TX, USA). 
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Results  
Over a six year time period, n=6,972 individuals had a least one adenoma removed at their 
index colonoscopic investigation (Figure 1).  There was a slight male predominance for 
adenoma patients, and the mean age at adenoma removal was 62.3 years.  The majority of 
adenomas were detected and removed from the colon, and 22% of individuals had multiple 
adenomas removed at their first investigation in this time period (Table 1).    
 
During a total of 44,724 person-years of follow-up, 193 patients were diagnosed with incident 
CRC.  The rate of progression was relatively stable over time, and was consistently higher in 
males than females (Figure 2).  Over this period, 0.43% of adenoma patients developed CRC 
each year, as shown in Table 2.  CRC risk was significantly elevated in males and in individuals 
aged 60 years or older with adenomas.  Rectal adenoma patients had an increased CRC risk 
(HR 1.70; 95% CI: 1.27-2.28) compared with those who had only colonic adenomas excised.  
No CRC developed in patients who had adenomas removed from both the colon and rectum.  
Those with tubulovillous or villous adenomas were more likely to develop CRC compared with 
those with tubular adenomas (HR 1.51; 95% CI: 1.02-2.23).   
 
Several factors were associated with reduced risk of CRC amongst adenoma cases, including 
being diagnosed with concurrent hyperplastic polyps (HR 0.45; 95% CI: 0.24-0.82), or 
subsequent polyps (Table 2).  Individuals diagnosed with multiple incident adenomas also had 
a decreased risk of CRC (HR 0.67; 95% CI: 0.45-0.97).  Sensitivity analysis removing the first 
year of follow-up revealed largely similar results (Supplementary Table 1).  As shown in Table 
2, the risk of progression to CRC was lower in patients diagnosed with only hyperplastic polyps 
(0.17% per year), compared with adenoma patients.  CRC risk in hyperplastic polyp patients 
did not differ significantly by sex, polyp location or multiplicity, however individuals aged 60-
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<80 years were at significantly increased risk of CRC compared with younger patients (data 
not shown).   
 
As outlined in Table 3, individuals diagnosed with adenomas were almost three times more 
likely to develop CRC than the general population (SIR 2.85; 95% CI: 2.61-3.25).  This 
heightened risk was observed in both males and females, for those with advanced adenomas, 
and after excluding cases in the first year of follow-up.  Unexpectedly, hyperplastic polyp 
patients also had an increased CRC risk compared with the general population (SIR 179; 95% 
CI: 145-233), which did not alter in sensitivity analysis excluding incident hyperplastic polyp 
patients who had a subsequent adenoma (SIR 180; 95% CI: 146-236).  Overall, an excess of 
125 and 18 CRC cases developed amongst adenoma and hyperplastic polyp patients, 
respectively. 
 
A post-hoc nested case-control study was conducted amongst CRC cases arising in adenoma 
and hyperplastic polyp cases (n=193, 82.5%) and matched controls whose medical notes were 
available for review, to determine further factors that may explain the excess CRC risk.  A 
small number of CRC cases were identified to have a personal history of polyposis syndromes 
(n=3) or family history of colorectal polyps (n=7), or both (n=1) and were excluded from 
further analysis since they are likely to be genetically predisposed to a greater CRC risk, leaving 
n=148 case-control pairs in the remaining adenoma analysis and n=34 pairs in the hyperplastic 
polyp analysis.  As shown in Table 4, a small proportion of excess CRC risk could be attributed 
to concurrent inflammatory bowel disease (OR 2.25; 95%CI: 0.98-5.17). Patients with large or 
right-sided incident polyps or adenomas with high-grade dysplasia had non-significantly 
increased risks of developing CRC.   
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Conversely, those with multiple adenomas, a CRC family history or an adenoma removed prior 
to the initiation of our study period (and therefore potentially undergoing surveillance) did not 
have an increased CRC risk.  Adenoma patients who had a full colonoscopy during the follow-
up period had a non-significant reduced risk of CRC, particularly if they had multiple (two or 
more) full colonoscopies performed (OR 0.59; 95% CI: 0.32-1.09). If patients had attended for 
investigative procedures other than full colonoscopy (for example sigmoidoscopy or barium 
enema), they had a significant increased risk of CRC (OR 2.18; 95% CI: 1.32-3.60).  In 
addition, individuals who did not attend for a planned procedure were at an increased risk of 
CRC, which was exaggerated if multiple appointments were missed (Table 4).    
 
Non-significant increased CRC risks were observed for individuals with multiple and/or right-
sided hyperplastic polyps, and those who did not attend for a planned follow-up investigation 
(data not shown).   
 
13 
 
Discussion  
Overall, annual CRC risk amongst individuals following polypectomy of adenomas in the non-
screening setting is 0.43%.  Despite undergoing polypectomy, CRC risk is significantly 
elevated for incident adenoma patients compared with the general population.  
 
The increased risk of CRC following adenoma removal observed in our study is in line with 
findings from a French study.(17)  In their analysis of 5,779 adenoma patients diagnosed 
between 1990 and 1999, 87 CRC were diagnosed, resulting in an SIR of 2.23 (95%CI 1.67-
2.92) for advanced adenomas.(17)  As a result of further case note review, a small proportion 
of CRC cases in the current study were found to be associated with genetic predisposition 
(6.9% overall, and 8.5% in advanced adenoma cases).  Applying these proportions to our 
overall SIR estimates would result in SIR of 2.65 and 2.53 for all and advanced adenomas, 
respectively, and are more comparable with the methods in the French study.(17)  The largest 
study to date, published from a Dutch population, only observed an elevated SIR (2.8; 95% CI 
2.5-3.1) in the second and third year of follow-up, which was then attenuated in later years.(18)  
This contrasts with our study findings, which illustrate a consistently increased CRC risk over 
a prolonged time period.  Earlier population-based studies of smaller sample size, tended to 
observe either no association or a reduced risk of CRC following adenoma removal.(15, 16, 
22)  Randomised controlled trials of flexible sigmoidoscopy have also mostly demonstrated a 
reduction in CRC incidence.(11, 12, 14)  Our findings indicate that the benefits seen for polyp 
removal in the tightly-controlled environment of trials and screened populations may not be 
replicated in the general population who are more likely to be symptomatic when presenting 
for clinical investigation.   
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As expected, being male or aged 60 years or older was associated with an increased risk of 
CRC following adenoma removal.(23, 24)  Individuals whose incident adenomas contained a 
villous component also had increased CRC risk, which is consistent with previous reports.(23)  
Other factors that would be expected to increase CRC risk, including a personal history of 
inflammatory bowel disease, presence of high-grade dysplasia in the adenomas and large 
adenoma size,(9, 25) were directly associated with CRC risk in the detailed case note review 
aspect of our study.  All of these findings are reassuring for the robustness of our data, but 
collectively, these factors only account for a relatively small proportion of the excess CRC 
cases found in this population.   
 
Several factors indirectly suggested that incomplete clearance of adenomas from the bowel 
may have led to the higher future CRC risk, which is consistent with previous study 
findings.(26-29)  Firstly, having only rectal adenomas diagnosed was associated with an 
increased risk of CRC, implying the colon may not have been examined. No CRC occurred 
amongst individuals who had adenomas diagnosed in both the colon and rectum.  Similarly, 
having multiple adenomas removed was inversely associated with CRC risk.  Finally, having 
concurrent adenoma and hyperplastic polyp removal at incident polypectomy (which suggests 
more thorough primary clearance of the bowel) or subsequent hyperplastic polyp detection 
(which indicates follow-up endoscopy) was associated with a reduced risk of CRC.   This was 
also corroborated by results from the case note review, in which individuals undergoing a full 
colonoscopy had decreased risks of CRC, whereas patients who had other investigative 
procedures such as incomplete colonoscopy, flexible sigmoidoscopy or barium enema had an 
increased risk of CRC.  These findings have implications for current surveillance guidelines 
following polypectomy.(9)  Our results suggest that a significant proportion of patients 
diagnosed with colorectal adenoma do not undergo full colonoscopy and adenoma clearance, 
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and this incurs an increased risk of CRC.  The reasons for this are unclear but merit further 
consideration.  While patient choice is foremost in decision making, understanding potential 
barriers for colonoscopy compliance is an important area for future research.  Having multiple 
full colonoscopies following incident adenoma removal was inversely associated with CRC 
risk, which argues for the benefit of continued surveillance.(30)  The increased yield of 
adenomas and CRC when performing full colonoscopy compared with other procedures is well 
established.(31-33)  
 
We also observed an unexpected increased CRC risk amongst individuals having only 
hyperplastic polyps removed.  The potential for hyperplastic polyps to be a marker of adenomas 
has been previously debated.(34, 35)  Our results do not support this finding, since an increased 
CRC risk remained when individuals with subsequent adenomas were removed from analysis.  
However, we were unable to account for adenomas detected after 2005 and undetected 
concurrent or subsequent adenomas may still explain the excess CRC risk seen.  Sessile 
serrated polyps represent another subset of serrated polyps, much rarer than hyperplastic 
polyps, and have only been well described in recent years.(36)  Sessile serrated polyps are more 
common in the proximal colon, are often multiple, are larger than typical hyperplastic polyps 
and are now accepted as the precursors to serrated pathway CRCs.(37, 38)  Sessile serrated 
polyps were not frequently reported by pathologists during this study period and it is likely 
many such polyps were misdiagnosed as hyperplastic polyps.(36, 39)  This is supported by our 
findings that multiple and right-sided ‘hyperplastic polyps’ carried an increased risk of CRC 
progression.   
 
Our study has several strengths, including its large size, length of follow-up and relevance to 
current practice, given the timeframe of adenoma patients studied. The population-based nature 
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of the study is important to emphasise, demonstrating CRC risk following polypectomy in a 
‘real world’ setting.  This is the first insight into this association in a UK population, amongst 
whom healthcare is free at the point of access.  Northern Ireland has a relatively stable 
population with limited migration,(40) therefore the completeness of passive follow-up is 
excellent. Furthermore, our results were not diluted with bowel cancer screening-detected 
adenomas/cancers since a screening programme only commenced in mid-2010.  This study 
does have some limitations that should be considered.  In the NICPR we did not have 
information on polyps diagnosed prior to 2000 or after 2005, or information on polyp size or 
detailed polyp topography.  However, we overcame these limitations by conducting a detailed 
note review in a nested case-control study.  The number of polyps in patients with more than 
one polyp was also underestimated due to the potential for SNOMED codes to have been 
entered only once by the reporting pathologist, if a patient had multiple polyps diagnosed of 
the same histological type at one episode.  Comparison with the case note review data suggests 
that approximately 10% of patients with multiple adenomas were misclassified as singular in 
the overall register.     
 
In conclusion, this large population-based study demonstrates that CRC risk remains 
significantly higher than that of the general population following adenoma removal, outside of 
screening programmes.  Our findings suggest the increased CRC risk may be partially due to 
incomplete examination and/or adherence to follow-up colonoscopies.  There is a need for full 
colonoscopy and adenoma clearance after a diagnosis of colorectal adenoma to reduce risk of 
subsequent CRC.  Further research is required to identify optimal surveillance protocols, and 
adherence to these, following adenoma removal.   
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Table 1. Characteristics of individuals diagnosed with incident colorectal adenomas in Northern Ireland 2000-
05. 
 
Variable Adenoma a 
register  
n= 6,972 (%)b 
Sex 
  Female 
  Male 
 
3,157 (45.3) 
3,815 (54.7) 
Age at diagnosis (years, mean ± SD) 62.7 ± 13.1 
Age groups at diagnosis (years) 
  16-<50  
  50-<60 
  60-<70 
  70-<80 
  ≥80 
 
1,237 (17.7) 
1,609 (23.1) 
1,916 (27.5) 
1,613 (23.1) 
597    (8.6) 
Year of diagnosis 
  2000 
  2001 
  2002 
  2003 
  2004 
  2005 
 
1,004 (14.4) 
990    (14.2) 
1,016 (14.6) 
1,280 (18.4) 
1,278 (18.3) 
1,404 (20.1) 
Topography of index polyp(s) 
  Colon only 
  Rectum only 
  Colon & rectum 
 
4,815 (69.1) 
1,687 (24.2) 
470    (6.7) 
Number of incident polyps a 
  1 
  ≥2 
 
5,414 (77.7) 
1,558 (22.4) 
Adenoma histology c 
  Tubular only   
  Villous/tubulovillous 
  Unspecified 
 
1,771 (25.4) 
3,368 (48.3) 
1,833 (26.3) 
Advanced adenomas d 3,819 (54.8) 
Subsequent adenoma e 870    (12.5) 
Subsequent hyperplastic polyp e 447    (6.4) 
 
Table 1 legend.  
a Incorporates n=858 individuals diagnosed with concurrent hyperplastic polyps as outlined in Figure 1. These 
are excluded from the ≥2 polyp number category unless multiple adenomas were diagnosed.  
b Percentages may not total 100 due to rounding. 
c Individuals with ≥1 villous or tubulovillous adenoma were classified as villous/tubulovillous, even if they also 
had a tubular adenoma at incident diagnosis.    
d Individuals with multiple adenomas or ≥1 villous/tubulovillous adenomas were classified as advanced.  The 
polyp register did not contain detailed information on polyp size. 
e Subsequent defined as ever diagnosis ≥6 months after incident polyps and up to date of colorectal cancer 
diagnosis or end of 31st December 2005. 
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Table 2. Colorectal cancer risk at least six months after incident colorectal adenoma diagnosis. 
 
Group No. 
cases 
Person-
years 
follow-up 
No. 
colorectal 
cancers 
Incidence, 
 % per year 
(95% CI) 
Adjusted a 
hazard ratio  
(95% CI) 
Adenoma register      
All 6,972 44,724 193 0.43 (0.37-
0.50) 
N/A 
Sex 
  Female 
  Male 
 
3,157 
3,815 
 
20,656 
24,068 
 
68 
125 
 
0.33 (0.26-
0.42) 
0.52 (0.43-
0.62) 
 
1.00 
1.69 (1.26-2.27) 
Age groups (years) 
  <50 
  50-<60 
  60-<70 
  70-<80 
  ≥80 
 
1,237 
1,609 
1,916 
1,613 
597 
 
8,817 
11,186 
12,529 
9,414 
2,778 
 
18 
29 
51 
60 
35 
 
0.20 (0.12-
0.32) 
0.26 (0.17-
0.37) 
0.41 (0.30-
0.53) 
0.64 (0.49-
0.82) 
1.26 (0.88-
1.75) 
 
1.00 
1.27 (0.71-2.29) 
1.99 (1.16-3.41) 
3.10 (1.83-5.26) 
6.16 (3.48-10.91) 
Topography of index polyp(s) 
  Colon 
  Rectum 
  Colon & rectum 
 
4,815 
1,687 
470 
 
30,686 
11,042 
2,997 
 
120 
73 
0 
 
0.39 (0.32-
0.47) 
0.66 (0.52-
0.83) 
0.00 (0.00-
0.00) 
 
1.00 
1.70 (1.27-2.28) 
/ 
No. incident adenomas  
  1 
  ≥2 
 
5,414 
1,558 
 
34,864 
9,861 
 
161 
32 
 
0.46 (0.39-
0.54) 
0.32 (0.22-
0.46) 
 
1.00 
0.67 (0.45-0.97) 
Morphology b 
  Tubular only   
  Villous/tubulovillous 
  Unspecified 
 
1,771 
3,368 
1,833 
 
11,524 
21,508 
11,692 
 
36 
97 
60 
 
0.31 (0.22-
0.43) 
0.45 (0.37-
0.55) 
0.51 (0.39-
0.66) 
 
1.00 
1.51 (1.02-2.23) 
1.68 (1.11-2.54) 
Advanced adenomas c 3,819 24,373 105 0.43 (0.35-
0.52) 
1.13 (0.83-1.54) 
Concurrent hyperplastic 
polyp(s) 
  Adenoma only 
  Adenoma+hyperplastic 
 
6,114 
858 
 
39,051 
5,674 
 
182 
11 
 
0.47 (0.40-
0.54) 
0.19 (0.10-
0.35) 
 
1.00 
0.45 (0.24-0.82) 
Subsequent adenoma d 870 6,572 20 0.30 (0.19-
0.47) 
0.72 (0.45-1.16) 
Subsequent hyperplastic polyp 
d 
447 3,507 4 0.11 (0.03-
0.29) 
0.31 (0.11-0.85) 
Hyperplastic register      
All 3,439 21,807 38 0.17 (0.12-
0.24) 
N/A 
 
Table 2 legend. 
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a Adjusted for age at incident polyp diagnosis (<50, 50-<60, 60-<70, 70-<80, ≥80 years), sex, year of incident 
polyp diagnosis (2000-2005), number of incident polyps diagnosed (1, ≥2) and subsequent adenoma diagnosed 
(yes/no). 
b Individuals with ≥1 villous or tubulovillous adenoma were classified as villous/tubulovillous, even if they also 
had a tubular adenoma at incident diagnosis.    
c Individuals with multiple adenomas or ≥1 villous/tubulovillous adenomas were classified as advanced.  The 
polyp register did not contain detailed information on polyp size. 
d Subsequent defined as ever diagnosis ≥6 months after incident polyps and up to date of colorectal cancer 
diagnosis or end of 31st December 2005. 
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Table 3. Standardised incidence ratios of colorectal cancer in individuals diagnosed with colorectal adenomas.  
 
 
Group No. 
cases 
No. CRC 
expected 
No. CRC 
observed 
SIR (95% CI) 
Adenomas a 
  All 
  Female 
  Male 
 
6,972 
3,157 
3,815 
 
68 
25 
45 
 
193 
68 
125 
 
2.85 (2.61-3.25) 
2.69 (2.30-3.33) 
2.76 (2.47-3.25) 
  Advanced adenomas b 3,819 38 105 1.75 (2.43-3.28) 
  All, excluding CRC in 1st year of follow-up 6,834 68 157 2.32 (2.10-2.69) 
Hyperplastic polyps 
  All 
  Female 
  Male 
  No subsequent adenoma 
 
3,464 
1,668 
1,796 
3,382 
 
23 
9 
14 
22 
 
41 
17 
24 
40 
 
1.79 (1.34-2.14) 
1.89 (1.34-2.78) 
1.67 (1.26-2.34) 
1.80 (1.46-2.36) 
 
 Table 3 legend.  
 CRC: Colorectal cancer. SIR: Standardised Incidence Ratios. 
a Incorporates n=858 individuals diagnosed with concurrent hyperplastic polyps as outlined in Figure 1. 
B Individuals with multiple adenomas or ≥1 villous/tubulovillous adenomas were classified as 
advanced.  The polyp register did not contain detailed information on polyp size. 
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Table 4. Colorectal cancer risk factors from a case note review of patients with colorectal adenoma who 
developed colorectal cancer and matched controls.  
 
 Adenoma patients  
Factor Controls 
n=148 (%) 
CRC cases 
n=148 (%) 
Odds ratio a   
(95% CI) 
Previous adenoma before 2000 
  No/unknown 
  Yes 
 
132 (89.2) 
16   (10.8) 
 
136 (91.9) 
12   (8.1) 
 
1.00 
0.69 (0.30-1.62) 
Personal history of IBD  
  No/unknown 
  Yes 
 
137 (92.6) 
11   (7.4) 
 
127 (85.8) 
21   (14.2) 
 
1.00 
2.25 (0.98-5.17) 
Family history of CRC 
  No/unknown 
  Yes 
 
127 (85.8) 
21   (14.2) 
 
130 (87.8) 
18   (12.2) 
 
1.00 
0.83 (0.42-1.65) 
Presence of HGD 
  No/unknown 
  Yes 
 
135 (91.2) 
13   (8.8) 
 
121 (81.8) 
27   (18.2) 
 
1.00 
3.33 (1.34-8.30) 
No. incident polyps 
  1 
  ≥2 
 
94   (63.5) 
54   (36.5) 
 
105 (71.0) 
43   (29.0) 
 
1.00 
0.70 (0.43-1.16) 
Right-sided polyp b 
  No/unknown 
  Yes, ≥1 right-sided 
 
134 (85.4) 
23   (14.7) 
 
124 (83.8) 
24   (16.2) 
 
1.00 
1.22 (0.66-2.28) 
Polyp size 
  Small/unknown 
  Large (≥1cm) 
 
112 (75.7) 
36   (24.3) 
 
103 (69.6) 
45   (30.4) 
 
1.00 
1.35 (0.81-2.24) 
Full colonoscopy c 
  No/unknown 
  Yes,1 
  Yes, ≥2 
 
37   (25.0) 
49   (33.1) 
62   (41.9) 
 
50   (33.8) 
45   (30.4) 
53   (35.8) 
 
1.00 
0.66 (0.36-1.21) 
0.59 (0.32-1.09) 
Any other investigations d 
  No/unknown 
  Yes,1 e 
  Yes, ≥2 
 
23   (15.5) 
62   (41.9) 
63   (42.6) 
 
18   (12.2) 
38   (25.7) 
92   (62.2)  
 
1.20 (0.58-2.47) 
1.00 
2.18 (1.32-3.60) 
Did not attend for planned follow-up procedure 
  No/unknown 
  Yes 
  Yes, missed>1 procedure 
 
137 (92.6) 
10   (6.8) 
1     (0.7) 
 
132 (89.2) 
13   (8.8) 
3     (2.0) 
 
1.00 
1.45 (0.62-3.41) 
3.64 (0.36-37.01) 
 
Table 4 legend. 
CRC: Colorectal cancer; HGD: High grade dysplasia; IBD: Inflammatory bowel disease. 
a Adjusted for matching criteria (age, sex, incident polyp type (adenoma/hyperplastic) and year of diagnosis at 
incident polyp. 
b Includes polyps detected in caecum, ascending colon, hepatic flexure and transverse colon  
c Number of full colonoscopies performed within 1 year prior to incident polyp diagnosis and before censor date 
(CRC diagnosis or matched follow-up time for controls).  
d Any other investigative procedures (excluding full colonoscopy) including incomplete or unspecified 
colonoscopy, proctoscopy, rigid or flexible sigmoidoscopy or barium enema performed within 1 year prior to 
incident polyp diagnosis. 
e Chosen as reference category to reflect that many individuals attended for a sigmoidoscopy or other non-full 
colonoscopy investigation at their first investigation, which was then followed up by a full colonoscopy.   
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Figure 1 legend.  
CRC: Colorectal cancer. 
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